Sight Sciences, Inc. (NASDAQ:SGHT) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET

Company Participants

Philip Trip Taylor - Investor Relations
Paul Badawi - Co-Founder and Chief Executive Officer
Alison Bauerlein - Chief Financial Officer
Matthew Link - Chief Commercial Officer

Conference Call Participants

Thomas Stephan - Stifel
Joseph Conway - Needham & Company
Felipe Lamar - Citi

Operator

Good day, and thank you for standing by. Welcome to the Sight Sciences Second Quarter 2024 Earnings Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn it over to your first speaker today, Trip Taylor, Investor Relations. Please go ahead.

Philip Trip Taylor

Thank you for participating in today's call. Presenting today are Sight Sciences Co-Founder and Chief Executive Officer, Paul Badawi; and Chief Financial Officer, Ali Bauerlein. Also in attendance is Sight Sciences' Chief Commercial Officer, Matt Link.

Earlier today, Sight Sciences released its financial results for the 3 months ended June 30, 2024, and narrowed revenue and adjusted operating expense guidance for full-year 2024. A copy of the press release is available on the company's website at investors.sightsciences.com.

I'd like to remind everyone that comments made by management today and answers to questions will include forward-looking statements within the meaning of the federal securities laws. These forward-looking statements include statements related to the company's anticipated financial performance, operating results and liquidity position, and ability to achieve cash flow breakeven, ability to achieve current and long-term strategic objectives, market opportunity, and the ability to enter new markets and capture market share, the pricing strategy and the impact of proposed rules on payment rates, product reimbursement, coverage and strategy, expectations regarding regaining commercial momentum, account utilization and engagement, clinical trial strategy and results, and the disposition of the patent infringement case.

Forward-looking statements are based on estimates and assumptions as of today are neither promises nor guarantees and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these statements.

A description of some of the risks and uncertainties that could cause actual results to differ materially from those indicated by the forward-looking statements on this call can be found in its public filings with the Securities and Exchange Commission, including in the Risk Factors section of the company's annual report on Form 10-K and quarterly reports on Form 10-Q.